Pharmacist-Led Intervention Reduces Medical Errors
For clinics with computerized medical records, a pharmacist-led intervention significantly reduces the risk of medical errors and is likely to be cost-effective.
Hyperacidity/GERD/Ulcers
SAFETY ALERT: FDA Warns of C. Difficile-Associated Diarrhea Risk with Proton Pump Inhibitors
The FDA has issued a warning that the use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD).
Proton Pump Inhibitor Use Ups Hip Fracture Risk for Women
Postmenopausal women are at a 35% increased risk of hip fractures if they regularly use proton pump inhibitors (PPIs), and that risk increases to more than 50% among women with a history of smoking.
Lansoprazole Does Not Improve Asthma Control in Children
For children with asthma without overt gastroesophageal reflux (GER), treatment with the proton pump inhibitor (PPI) lansoprazole is not associated with improved asthma control.
FIRST Omeprazole and FIRST Lansoprazole Compounding Kits Available
CutisPharma has launched the FIRST Omeprazole and FIRST Lansoprazole oral suspension compounding kits for pharmacists.
RECALL: Novartis Recalls Select Excedrin, NoDoz, Bufferin, and Gas-X Prevention Products
Novartis Consumer Health announced a voluntary recall of all lots of select bottle packaging configurations of the Excedrin product line and NoDoz (caffeine) products with expiry dates of December 20, 2014 or earlier, as well as all lots of Bufferin (aspirin) and Gas-X Prevention (simethicone) products with expiry dates of December 20, 2013 or earlier.
Peptic Ulcer Patient Information Fact Sheet
This patient information fact sheet provides information on the definition, causes, symptoms, risks, diagnostic tests and treatments for peptic ulcers.
Dexilant Labeling Updated with Plavix Coadministration Information
Takeda announced that it has updated the product labeling for Dexilant (dexlansoprazole) to include information demonstrating that Dexilant had no clinically important effect on exposure to the active metabolite of clopidogrel (Plavix; Bristol-Myers Squibb and Sanofi) or clopidogrel-induced platelet inhibition.
Nexium IV Gains Indication for GERD in Pediatric Patients
AstraZeneca announced that the FDA has approved Nexium IV (esomeprazole sodium for injection) for use in children >1 month of age for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis when oral therapy is not possible or appropriate.
RECALL: Teva’s Lansoprazole Delayed-Release Orally Disintegrating Tablets Withdrawn
Teva Pharmaceuticals has voluntarily withdrawn its lansoprazole delayed-release orally disintegrating tablets (ODT) product from distribution after the FDA received reports of clogged and blocked oral syringes and feeding tubes when the drug is administered as a suspension through these devices.
